EA035506B1 - Способ конъюгации (варианты), модифицированный терапевтический белок и способ получения водорастворимого полимера (варианты) - Google Patents

Способ конъюгации (варианты), модифицированный терапевтический белок и способ получения водорастворимого полимера (варианты) Download PDF

Info

Publication number
EA035506B1
EA035506B1 EA201790935A EA201790935A EA035506B1 EA 035506 B1 EA035506 B1 EA 035506B1 EA 201790935 A EA201790935 A EA 201790935A EA 201790935 A EA201790935 A EA 201790935A EA 035506 B1 EA035506 B1 EA 035506B1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
soluble polymer
water
factor
alpha
Prior art date
Application number
EA201790935A
Other languages
English (en)
Russian (ru)
Other versions
EA201790935A1 (ru
Inventor
Юрген Зикманн
Штефан Хайдер
Ханспетер Роттенштайнер
Петер Турецек
Original Assignee
Баксалта Инкорпорейтид
Баксалта Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/488,043 external-priority patent/US8809501B2/en
Application filed by Баксалта Инкорпорейтид, Баксалта Гмбх filed Critical Баксалта Инкорпорейтид
Publication of EA201790935A1 publication Critical patent/EA201790935A1/ru
Publication of EA035506B1 publication Critical patent/EA035506B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Water Supply & Treatment (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201790935A 2012-05-16 2013-05-16 Способ конъюгации (варианты), модифицированный терапевтический белок и способ получения водорастворимого полимера (варианты) EA035506B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261647814P 2012-05-16 2012-05-16
US13/488,043 US8809501B2 (en) 2009-07-27 2012-06-04 Nucleophilic catalysts for oxime linkage

Publications (2)

Publication Number Publication Date
EA201790935A1 EA201790935A1 (ru) 2017-12-29
EA035506B1 true EA035506B1 (ru) 2020-06-25

Family

ID=48579473

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201790935A EA035506B1 (ru) 2012-05-16 2013-05-16 Способ конъюгации (варианты), модифицированный терапевтический белок и способ получения водорастворимого полимера (варианты)
EA201492115A EA028186B9 (ru) 2012-05-16 2013-05-16 Способ конъюгации водорастворимого полимера с терапевтическим белком (варианты) и полученный модифицированный белок

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201492115A EA028186B9 (ru) 2012-05-16 2013-05-16 Способ конъюгации водорастворимого полимера с терапевтическим белком (варианты) и полученный модифицированный белок

Country Status (12)

Country Link
EP (3) EP2849794A1 (enExample)
JP (5) JP6195611B2 (enExample)
KR (4) KR102287040B1 (enExample)
CN (2) CN109620963B (enExample)
AU (1) AU2013204754C1 (enExample)
BR (1) BR112014028636B1 (enExample)
CA (1) CA2873756C (enExample)
EA (2) EA035506B1 (enExample)
MX (1) MX360594B (enExample)
NZ (4) NZ738844A (enExample)
SG (3) SG11201407597XA (enExample)
WO (2) WO2013173543A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
WO2018087727A1 (en) * 2016-11-14 2018-05-17 Novartis Ag Methods and compositions for treatment of cartilage damage and arthritis
JP7002036B2 (ja) * 2016-11-17 2022-01-20 パナソニックＩｐマネジメント株式会社 膜電極接合体および固体酸化物形燃料電池
WO2018112669A1 (en) * 2016-12-23 2018-06-28 Realist Pharma, Inc. Ganglioside carbohydrate structures and uses thereof
CN108503901B (zh) * 2018-04-17 2020-07-07 哈尔滨工业大学 一种抗菌普鲁兰多糖/壳聚糖复合食品包装膜的制备方法
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
EP3914711A2 (en) 2019-01-23 2021-12-01 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
MX2023009987A (es) 2021-02-26 2023-09-06 Regeneron Pharma Tratamiento de la inflamacion con glucocorticoides e inhibidores de angiopoyetina tipo 7 (angptl7).
JPWO2023171638A1 (enExample) 2022-03-07 2023-09-14
WO2025133203A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012850A2 (en) * 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
WO2011017055A2 (en) * 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
WO2012016131A1 (en) * 2010-07-30 2012-02-02 Baxter International Inc. Nucleophilic catalysts for oxime linkage

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
AU7097094A (en) * 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
JP2003533537A (ja) 2000-05-16 2003-11-11 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
JP4758608B2 (ja) 2001-11-07 2011-08-31 ネクター セラピューティックス 分枝ポリマーおよびそれらの結合体
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
KR101045401B1 (ko) 2002-09-11 2011-06-30 프레제니우스 카비 도이치란트 게엠베하 하이드록시알킬 전분 유도체
JP4698579B2 (ja) 2003-04-08 2011-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 可逆的ｐｅｇ化薬物
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
EP1653991A2 (en) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugates of a polymer and a protein linked by an oxime linking group
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004296855B2 (en) 2003-12-03 2011-01-06 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
EP1776389B1 (en) 2004-08-12 2016-06-29 Lipoxen Technologies Limited Sialic acid derivatives
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
PL1835938T3 (pl) 2004-12-27 2014-01-31 Baxalta Inc Koniugaty polimer-czynnik von Willebrandta
BRPI0611872B8 (pt) 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
BRPI0720282B8 (pt) * 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
KR101560541B1 (ko) * 2012-04-13 2015-10-19 아우토리브 디벨롭먼트 아베 에어백 모듈과 스티어링 휠의 조립체
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012850A2 (en) * 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
WO2011017055A2 (en) * 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
WO2012016131A1 (en) * 2010-07-30 2012-02-02 Baxter International Inc. Nucleophilic catalysts for oxime linkage

Also Published As

Publication number Publication date
WO2013173543A1 (en) 2013-11-21
KR20150008192A (ko) 2015-01-21
CN104487095B (zh) 2018-12-07
EP4019049A1 (en) 2022-06-29
KR102326360B1 (ko) 2021-11-15
JP6560712B2 (ja) 2019-08-14
EP2849795B1 (en) 2022-04-06
MX2014013919A (es) 2015-06-05
JP2020111599A (ja) 2020-07-27
EA201492115A1 (ru) 2015-05-29
JP6711935B2 (ja) 2020-06-17
JP6195611B2 (ja) 2017-09-13
EA028186B9 (ru) 2018-05-31
JP2019089810A (ja) 2019-06-13
SG11201407597XA (en) 2014-12-30
CN109620963B (zh) 2022-10-28
SG10201701780RA (en) 2017-04-27
SG10201911328QA (en) 2020-01-30
KR102237306B1 (ko) 2021-04-08
JP2015520163A (ja) 2015-07-16
KR20210099187A (ko) 2021-08-11
EP2849795A1 (en) 2015-03-25
MX360594B (es) 2018-11-09
NZ738846A (en) 2019-05-31
NZ701945A (en) 2016-10-28
BR112014028636B1 (pt) 2022-09-20
JP7304402B2 (ja) 2023-07-06
KR102110622B1 (ko) 2020-05-14
BR112014028636A2 (enExample) 2017-08-15
CN109620963A (zh) 2019-04-16
CA2873756A1 (en) 2013-11-21
NZ738844A (en) 2018-12-21
JP2022034075A (ja) 2022-03-02
NZ724828A (en) 2018-02-23
CA2873756C (en) 2022-08-16
EA028186B1 (ru) 2017-10-31
KR20210041629A (ko) 2021-04-15
KR102287040B1 (ko) 2021-08-09
AU2013204754C1 (en) 2018-10-11
JP2017145260A (ja) 2017-08-24
WO2013173557A1 (en) 2013-11-21
KR20200053636A (ko) 2020-05-18
AU2013204754B2 (en) 2015-11-05
CN104487095A (zh) 2015-04-01
EP2849794A1 (en) 2015-03-25
EA201790935A1 (ru) 2017-12-29
HK1209024A1 (en) 2016-03-24
JP7014844B2 (ja) 2022-02-01

Similar Documents

Publication Publication Date Title
US20210163527A1 (en) Nucleophilic catalysts for oxime linkage
US11564992B2 (en) Nucleophilic catalysts for oxime linkage
EP2654794B1 (en) Materials and methods for conjugating a water soluble fatty acid derivative to a protein
EP2598172B1 (en) Nucleophilic catalysts for oxime linkage
EA035506B1 (ru) Способ конъюгации (варианты), модифицированный терапевтический белок и способ получения водорастворимого полимера (варианты)
US20130310546A1 (en) Nucleophilic catalysts for oxime linkage and use of nmr analyses of the same
AU2017276255B2 (en) Nucleophilic Catalysts for Oxime Linkage
HK40076576A (en) Methods for preparing therapeutic protein-polymer conjugates
HK40077427A (en) Nucleophilic catalysts for oxime linkage
HK40009331A (en) Nucleophilic catalysts for oxime linkage
EA044273B1 (ru) Способ конъюгирования водорастворимого полимера с терапевтическим белком
HK1209024B (en) Methods for preparing therapeutic protein-polymer conjugates
HK1186115A (en) Nucleophilic catalysts for oxime linkage
HK1186115B (en) Nucleophilic catalysts for oxime linkage
HK1191220A (en) Materials and methods for conjugating a water soluble fatty acid derivative to a protein
HK1191220B (en) Materials and methods for conjugating a water soluble fatty acid derivative to a protein

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM